Names without a link are companies not yet registered in OpenBizGraph
§05
Network
NETWORK
Loading the relationship graph...
Drag to move · click to open
§06
History
86 EVENTS
Established in 1942 as a company controlling the export of Toyama household medicines. Founded Dai-Do Pharmaceutical Trading Control Co., Ltd.
Established as a company controlling the export of Toyama household medicine to Southeast Asia, where many Japanese residents lived. Founded Daito Pharmaceutical Trade Control Co., Ltd.
Founded in 1942 as an export control company for Toyama Household Medicine, the company celebrated its 10th anniversary of stock listing in 2020.
Established Dai Toa Pharmaceutical Trading Control Co., Ltd. in 1942 (Showa 17)
Founded: June 1942 (Showa 17).
In 1948, changed the company name to Dai-Do Trading Co., Ltd.
Changed the company name to Daito Trade Co., Ltd.
Changed company name to Dai To Trading Co., Ltd. in 1948 (Showa 23)
In 1949, began manufacturing prescription drugs.
Commenced manufacturing of allocation medicines.
Started manufacturing distribution-use pharmaceuticals in 1949 (Showa 24)
In 1950, established the raw material wholesale division and began selling raw materials.
Established the Active Pharmaceutical Ingredient Wholesale Division and began selling APIs in 1950 (Showa 25)
From 1961, the national health insurance system began, and medical care became widely available.
In 1971, established a research laboratory in Toyama City.
Established a research institute in Toyama City.
Established a research institute in Toyama City in 1971 (Showa 46)
In 1976, began manufacturing generic medical drugs.
Commenced manufacturing of medical drugs (generic drugs).
Started manufacturing generic medical drugs in 1976 (Showa 51)
In 1979, began manufacturing raw materials.
Commenced manufacturing of active pharmaceutical ingredients.
Started manufacturing APIs in 1979 (Showa 54)
In 1985, began manufacturing OTC drugs.
Started manufacturing OTC pharmaceuticals
Started manufacturing OTC drugs in 1985 (Showa 60)
In 1987, acquired Daiwa Pharmaceutical Industry Co., Ltd. (now Daito Co., Ltd. Shimokoi Factory) as a subsidiary.
Acquired Daiwa Pharmaceutical Industries Co., Ltd. (now Daito Corporation, Shimauchi Factory) as a subsidiary
Made Daiwa Pharmaceutical Industries Co., Ltd. (now Daito Co., Ltd. Shimokoi Factory) a subsidiary in 1987 (Showa 62)
In 1989, began contract manufacturing of new drug intermediates.
Commenced contract manufacturing of new drug intermediates
Started contract manufacturing of new drug intermediates in 1989 (Showa 64)
In 1991, changed the company name to Daito Co., Ltd.
Changed the company name to Daito Corporation
Changed company name to Daito Co., Ltd. (current name) in 1991 (Heisei 3)
In 1993, established the third manufacturing building.
Established a new third formulation building
Established the Third Formulation Building in 1993 (Heisei 5)
In 1999, established the third raw material building.
Established a new third active pharmaceutical ingredient building
Established the Third Active Pharmaceutical Ingredient Building in 1999 (Heisei 11)
With the 2005 revision of the Pharmaceutical Affairs Law, the contract manufacturing business for medical drugs expanded.
In 2007, listed shares on the Tokyo Stock Exchange.
Established a new fifth active pharmaceutical ingredient building
Fully acquired Daiwa Pharmaceutical Industries Co., Ltd. (now Daito Corporation, Shimauchi Factory) as a subsidiary
In 2007 (Heisei 19), the Fifth Active Pharmaceutical Building was newly established, and Daito Pharmaceutical Industry Co., Ltd. (now Daito Co., Ltd. Shimokui Plant) was fully acquired as a subsidiary.
In 2008, established Daito Pharmaceuticals America, Inc. in Illinois, USA.
Established Daito Pharmaceuticals America, Inc. in Illinois, USA
Established a new sixth formulation building
In 2008 (Heisei 20), Daito Pharmaceuticals America, Inc. was established in Illinois, USA, and the Sixth Formulation Building was newly established.
Listed on the Second Section of the Tokyo Stock Exchange in 2010.
Listed on the Second Section of the Tokyo Stock Exchange
In 2010 (Heisei 22), the company was listed on the Second Section of the Tokyo Stock Exchange.
Reclassified to the First Section of the Tokyo Stock Exchange in 2011.
Reclassified to the First Section of the Tokyo Stock Exchange
In 2011 (Heisei 23), the company was moved to the First Section of the Tokyo Stock Exchange, and Daito Pharmaceuticals America, Inc.
Acquired Anhui Weina Life Science Technology Development Co., Ltd. (now Da Tong Pharmaceutical (China) Co., Ltd.) as a subsidiary in 2012.
Acquired Anhui Weina Life Science Technology Development Co., Ltd. as a subsidiary
In 2012 (Heisei 24), Anhui Weina Life Science and Technology Development Co., Ltd. was acquired as a subsidiary (now Daitoki Pharmaceutical (China) Co., Ltd.).
Established a new formulation building at Da Tong Pharmaceutical (China) Co., Ltd. in 2014. Opened the Seventh Formulation Building for high pharmacological active formulation manufacturing.
Established a formulation building at Daikou Pharmaceutical (China) Co., Ltd.
Established a new seventh formulation building (high pharmacological activity formulation production)
Established the first factory building of Daiwa Pharmaceutical Industries (now Daito Corporation, Shimauchi Factory)
In 2014 (Heisei 26), a formulation building was newly established at Daitoki Pharmaceutical (China) Co., Ltd., the Seventh Formulation Building was newly established (for high pharmacological activity formulations), and the First Factory Building of Daito Pharmaceutical (now Daito Co., Ltd. Shimokui Plant) was newly established.
Transitioned from a company with a board of auditors to one with an audit and other committees in 2015.
Transitioned from a company with a board of auditors to a company with an audit committee
Established a new sixth active pharmaceutical ingredient building
In 2015 (Heisei 27), the company transitioned from a company with a board of auditors to a company with an audit committee, and the Sixth Active Pharmaceutical Building was newly established.
Established a high pharmacology R&D Center in 2017.
Established a high pharmacology R&D center
In 2017 (Heisei 29).
Opened the Eighth Formulation Building for high pharmacological active formulation manufacturing in 2018.
Established a new eighth formulation building (high pharmacological activity formulation production)
Celebrated the 10th anniversary of the stock listing.
In 2020, the company celebrated its 10th anniversary since going public.
Established a Quality Assurance Building in 2021.
New Quality Assurance Building established
Moved to the Prime Market following the Tokyo Stock Exchange market classification review in 2022.
Transitioned to the Prime Market following a review of market classifications by the Tokyo Stock Exchange
New Seventh Active Pharmaceutical Ingredient Building established
Opened the Tenth Formulation Building in 2023.
New Tenth Formulation Building established
Established a Comprehensive Research Center in 2024.
New Comprehensive Research Center established
Absorbed and merged with Daiwa Pharmaceutical Industries Co., Ltd. (now Daito Co., Ltd. Shimokoi Factory) in 2025.
Absorbed and merged with Daiwa Pharmaceutical Industries Co., Ltd. (now Daito Co., Ltd. Shimokoi Factory)
§07
News
2 ARTICLES
Daito Corporation Launches Four New Medical Drugs
Daito Corporation launched four new medical drugs, including Capecitabine Tablets 300mg "Takata" and Lacosamide products, on December 5, 2025. This is expected to expand options in medical settings.
Notice of the Passing of Kiyotaka Kido, President of Daiwa Pharmaceutical Industry Co., Ltd.
Kiyotaka Kido, President of Daiwa Pharmaceutical Industry Co., Ltd., passed away peacefully on May 9, 2025. He was 70 years old. Daiwa Corporation sincerely thanks him for his lifelong friendship and mourns his passing.